Companies sometimes promote new products, but withhold the detailed findings until much later. The consequences for both consumers and the health system are vast.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions. Headlines proclaimed a potential game changer in treating cardiovascular disease. And company shares quickly soared, from $3 a share to about $20.
Vascepa is Amarin's only product. The company wants to turn its pill made of purified fish oil into a cash cow, allowing it to staff up both in the United States and abroad so it can sell doctors and millions of consumers on its medical benefits. Although the product has been on the market for more than five years, its first TV ad campaign rolled out this summer in anticipation of the study findings.
Except there is one problem. The particulars of the scientific study on which this claim was based remain a mystery.
Amarin's preliminary announcement came via a news release on Sept. 24. The company plans to release detailed findings in November at the national American Heart Association conference. Then early next year, it plans to seek Food and Drug Administration approval to use the drug as a preventive for a range of heart conditions, beyond its current role targeting high triglyceride levels.
In the interim, a battle is brewing among physicians, cardiovascular experts and pharma watchers who say Vascepa brings to the foreground troubling trends in the marketing and advertising of new drugs. Companies sometimes promote new products, but withhold the detailed findings until much later. The consequences for both consumers and the health system are vast.
"Until all the data is available for review by the public and medical community, it's really premature to see some of the cheerleading that's being done," said Dr. Eric Strong, a hospitalist and clinical assistant professor at Stanford School of Medicine. "It's harder to change people's minds once you have these rosy pictures."
John Thero, Amarin's CEO, argued that the imminent release of the drug's complete picture should alleviate those concerns.
In unveiling topline findings in a news release, he said, the company's playbook doesn't diverge from that of other pharmaceutical makers, and provides a necessary level of disclosure for shareholders.
But it's the specifics in the data — for instance, which patients benefited, by how much, their absolute risk reduction and which precise conditions saw improvement — that illustrate whether a product is cost-effective, said medical and drug experts.
That's especially true in the case of Vascepa, whose manufacturer is working hard to convince people the product is clinically superior to ordinary fish oil supplements. Fish oil, which can retail for a few dollars a bottle, has long been promoted as a preventive for heart disease. But the substance has never held up in clinical trials as a way to systematically lower disease risk, said experts.
That's where Amarin's product is superior, Thero said.
The manufacturer has tried to limit competition by seeking to block other fish oil products —arguing to the U.S. International Trade Commission that omega-3 supplements aren't equivalents, and calling on the FDA to block a chemical component of fish oil, known as EPA and marketed by a number of supplement companies, from being sold as a dietary supplement. Amarin hasn't yet prevailed.
Preston Mason, a biologist who consults for Amarin and has advocated on its behalf, argued that ordinary fish oil supplements carry risks because they are not regulated or approved by the FDA, which does oversee prescription drugs like Vascepa.
How Vascepa performs against regular fish oil remains unknown. Amarin's trial compared the drug against a placebo, not over-the-counter supplements.
Vascepa itself isn't new. It was approved in 2012 as a remedy for extremely high triglyceride levels, which can put patients at risk for pancreatic problems. But reducing that fat hadn't been conclusively tied to, say, lowering the risk of heart attacks, or other major cardiac problems.
That link, ostensibly, is what Amarin is trying now to assert. And there's plenty of money to be made if it succeeds.
As of last December, Vascepa retailed for about $280 for a month-long supply, a list price increase of 43 percent over five years, though the company says its net sale price has stayed the same. (That difference would come if Amarin increased the size of rebates, or discounts it provides, commensurate with price hikes.)
Now, citing the drug's potentially increased value, Amarin has declined to say whether it will change the price again — though Thero said he sees greater profit potential if the company increases sales volume rather than price.
This gets at the crux of this debate. If a company makes available the technical details of a product, but only after hyping the findings, and if the details undercut some of that buzz — is it too late?
Dr. Khurram Nasir, a Yale cardiologist, acknowledged that it's unclear how effective Vascepa really is, but maintained those ambiguities will be cleared up soon enough.
"As the findings reveal themselves, there will be a lot of discussion around cost effectiveness, and whether this is worth the spend," Nasir said.
Mason, the Amarin scientist, said FDA scrutiny can also alleviate concerns about overhype.
But others worry the perception of Vascepa's effectiveness is now set.
"People are weighing in with really strong language, without enough information," said Dr. Lisa Schwartz, who co-directs the Dartmouth Institute's Center for Medicine and Media and studies effective scientific communication.
That has both clinical and financial consequences, she added. Doctors are more likely to prescribe a product that's been heavily promoted, even if subsequent discussion indicates the drug isn't as powerful as initially implied. And manufacturers can cash in, whether through increased company stock market value or by charging higher list prices.
For Vascepa, the central question is which specific heart conditions saw risk reduction, she and others said. In its news release, Amarin noted a "composite outcome" — that is, the 25 percent relative improvement encompassed all conditions for which the researchers tested.
"People are saying, Wow, it reduced heart attack, stroke and blah, blah, blah — when it may just reduce the least important one," said Dr. Steven Woloshin, Schwartz's research partner.
Another issue: The Vascepa trial focused on a specific population — patients with high triglyceride levels plus elevated risk of cardiovascular disease or diabetes who were already taking a daily statin. That means any proof of benefit is limited to that group.
Woloshin and Schwartz both suggested that nuance could get lost in translation. "It is this much narrower, high-risk population," Schwartz said.
Woloshin added, "The fear is [the message] would generalize to anyone with high triglycerides."
This concern is amplified by a 2016 court settlement in which the FDA permitted Amarin to market Vascepa to audiences for whom it hasn't been specifically approved — so long as the company doesn't say anything untrue about the drug.
Thero said Amarin's marketing of Vascepa has stayed, and will remain, consistent with what is factual and relevant.
"We are proceeding consistently with what the FDA has guided," he said.
But, some experts said, the 2016 settlement could unlock the door to wider marketing of Vascepa's off-label use, implying the pill benefits more people than it actually does.
"They'll take pains to show how different this is from everything out there … and its results in these populations," said Dr. Ameet Sarpatwari, an epidemiologist and lawyer at Harvard Medical School, who studies the pharmaceutical industry. "What they can't do is say it will be beneficial to these other populations. But they can hint at that."
Despite federal rules requiring plans to keep up-to-date directories, consumers may lack access to clear information about which health plans have 'narrow networks' of providers or which hospitals and doctors are in or out of an insurer's network.
As a breast cancer survivor, Donna Catanuchi said she knows she can't go without health insurance. But her monthly premium of $855 was too high to afford.
"It was my biggest expense and killing me," said Catanuchi, 58, of Mullica Hill, N.J.
A "navigator" who helps people find coverage through the Affordable Care Act found a solution. But it required Catanuchi, who works part time cleaning offices, to switch to a less comprehensive plan, change doctors, drive farther to her appointments and pay $110 a visit out-of-pocket — or about three times what she was paying for her follow-up cancer care.
She now pays $40 a month for coverage, after she qualified for a substantial government subsidy.
Catanuchi's switch to a more affordable but restrictive plan reflects a broad trend in insurance plan design over the past few years. The cheaper plans offer far narrower networks of doctors and hospitals and less coverage of out-of-network care. But many consumers are overwhelmed or unaware of the trade-offs they entail, insurance commissioners and policy experts say.
With enrollment for ACA health plans beginning Nov. 1, they worry that consumers too often lack access to clear information about which health plans have "narrow networks" of medical providers or which hospitals and doctors are in or out of an insurer's network, despite federal rules requiring plans to keep up-to-date directories.
"It's very frustrating for consumers," said Betsy Imholz, who represents the advocacy group Consumers Union at the National Association of Insurance Commissioners. "Health plan provider directories are often inaccurate, and doctors are dropping in and out all the time."
These more restrictive plans expose people to larger out-of-pocket costs, less access to out-of-network specialists and hospitals, and "surprise" medical bills from unforeseen out-of-network care.
More than 14 million people buy health insurance on the individual market — largely through the ACA exchanges, and they will be shopping anew this coming month.
Both have more restrictive networks and offer less out-of-network coverage compared with preferred provider organizations (PPOs), which represented 21 percent of health plans offered through the ACA exchanges in 2018, according to Avalere, a health research firm in Washington, D.C.
PPOs typically provide easier access to out-of-network specialists and facilities, and partial — sometimes even generous — payment for such services.
Measured another way, the number of ACA plans offering any out-of-network coverage declined to 29 percent in 2018 from 58 percent in 2015, according to a recent analysis by the Robert Wood Johnson Foundation.
For example, in California, HMO and EPO enrollment through Covered California, the state's exchange, grew from 46 percent in 2016 to 70 percent in 2018, officials there said. Over the same period, PPO enrollment declined from 54 percent to 30 percent.
In contrast, PPOs have long been and remain the dominant type of health plan offered by employers nationwide. Forty-nine percent of the 152 million people and their dependents who were covered through work in 2018 were enrolled in a PPO-type plan. Only 16 percent were in HMOs, according to the Kaiser Family Foundation's annual survey of employment-based health insurance.
The good news for people buying health insurance on their own is that the trend toward narrow networks appears to be slowing.
"When premiums shot up over the past few years, insurers shifted to more restrictive plans with smaller provider networks to try and lower costs and premiums," said Chris Sloan, a director at Avalere. "With premium increases slowing, at least for now, that could stabilize."
Some research supports this prediction. Daniel Polsky, a health economist at the University of Pennsylvania, found that the number of ACA plans nationwide with narrow physician networks declined from 25 percent in 2016 to 21 percent in 2017.
Polsky is completing an analysis of 2018 plans and expects the percent of narrow network plans to remain "relatively constant" for this year and into 2019.
"Fewer insurers are exiting the marketplace, and there's less churn in the plans being offered," said Polsky. "That's good news for consumers."
Insurers may still be contracting with fewer hospitals, however, to constrain costs in that expensive arena of care, according to a report by the consulting firm McKinsey & Co. It found that 53 percent of plans had narrow hospital networks in 2017, up from 48 percent in 2014.
"Narrow networks are a trade-off," said Paul Ginsburg, a health care economist at the Brookings Institution. "They can be successful when done well. At a time when we need to find ways to control rising health care costs, narrow networks are one legitimate strategy."
Ginsburg also notes that there's no evidence to date that the quality of care is any less in narrow versus broader networks, or that people are being denied access to needed care.
Mike Kreidler, Washington state's insurance commissioner, said ACA insurers in that state "are figuring out they can't get away with provider networks that are inadequate to meet people's needs."
"People have voted with their feet, moving to more affordable choices like HMOs but they won't tolerate draconian restrictions," Kreidler said.
The state is stepping in, too. In December 2017, Kreidler fined one insurer — Coordinated Care — $1.5 million for failing to maintain an adequate network of doctors. The state suspended $1 million of the fine if the insurer had no further violations. In March 2018, the plan was docked another $100,000 for similar gaps, especially a paucity of specialists in immunology, dermatology and rheumatology. The $900,000 in potential fines continues to hang over the company's head.
Pennsylvania Insurance Commissioner Jessica Altman said she expects residents buying insurance in the individual marketplace for 2019 to have a wider choice of providers in their networks.
"We think and hope insurers are gradually building more stable networks of providers," said Altman.
New State Laws
Bad publicity and recent state laws are pushing insurers to modify their practices and shore up their networks.
About 20 states now have laws restricting surprise bills or balance billing, or which mandate mediation over disputed medical bills, especially those stemming from emergency care.
Even more have rules on maintaining accurate, up-to-date provider directories.
The problem is the laws vary widely in the degree to which they "truly protect consumers," said Claire McAndrew, a health policy analyst at Families USA, a consumer advocacy group in Washington, D.C. "It's a patchwork system with some strong consumer protections and a lot of weaker ones."
"Some states don't have the resources to enforce rules in this area," said Justin Giovannelli, a researcher at the Center on Health Insurance Reforms at Georgetown University. "That takes us backward in assuring consumers get coverage that meets their needs."
Like many Republican candidates struggling to explain how they could support protections for preexisting conditions while also supporting changes that would gut them, Rep. Tom MacArthur has offered vague but persistent promises to shield Americans with medical conditions.
EDGEWATER PARK, N.J. — Not long ago many voters knew little about Tom MacArthur. A low-key moderate Republican congressman in a district that twice went for Barack Obama, he burnished his reputation as the guy who worked with Democrats to help rebuild in the years after Hurricane Sandy.
Now, as he wages a bitter fight for re-election to a seat he won by 20 percentage points just two years ago, even some of his supporters have turned virulently against him. The reason? His new reputation as the turncoat whose legislation almost repealed the Affordable Care Act.
Like many Republican candidates struggling to explain how they could support protections for preexisting conditions while also supporting changes that would gut them, MacArthur has offered vague but persistent promises to shield Americans with medical conditions.
But he also wrote the Republican legislation that would have allowed states to charge those Americans higher premiums or limit what services are covered, gaining enough support for the repeal bill to clear the House last year.
As such, MacArthur's candidacy has become a kind of Rorschach test for Republicans' repeated attempts to repeal and otherwise undermine the Affordable Care Act — and how much candidates in swing districts will pay for those efforts.
If this New Jersey district is any indication, it could be a lot.
Sue Coleman, 64, split her ballot in 2016, voting for MacArthur and Hillary Clinton. "I thought he was a moderate, so I voted for him," she said. Today, she feels so angry that she arrived at a recent political event at the 45th Street Pub here wearing an unruly wig, a full beard and mustache paired with a dark suit and blood-red tie — imitating one of the congressman's top aides who has become a familiar gatekeeper as she and others have personally lobbied MacArthur. The crowd laughed and cheered.
Earlier that day, dozens of people, most of them women, gathered in a strip mall parking lot before scattering to knock on doors on behalf of MacArthur's Democratic challenger, Andy Kim. MacArthur "didn't listen to the people," said Nancy Keegan, 57, of Delran Township, N.J., as she stood with her sisters.
Some of the volunteers couldn't help but point out that the high school across the street was where MacArthur held a nearly five-hour town hall last year that made national headlines for the irate crowd of constituents and protesters who shouted down explanations of his attempts to resuscitate the repeal effort. MacArthur has made fewer, and more limited, public appearances since then.
In a sign of the race's power to help Democrats reclaim the House, members of Planned Parenthood, NARAL and Rep. Katherine Clark (D-Mass.) were on hand to energize the sweatshirt- and sneaker-clad crowd. While it has been about a year and a half since MacArthur bolstered the Republican repeal effort, the anger hasn't faded. Said Susan Harper, 64, also of Delran Township and Keegan's sister: "I don't think that's going away."
MacArthur, 58, a wealthy insurance executive who has received hundreds of thousands of dollars in corporate contributions and invested millions of his own in his campaigns, is locked in "a true toss-up" this year, said David Wasserman, an editor at the Cook Political Report. Kim, 36, — a former Obama administration national security official — had raised $750,000 more than MacArthur had by the end of September.
Trump won MacArthur's 3rd Congressional District — which spans the state from the suburbs outside Philadelphia to the tourist destinations and retirement communities of the Jersey Shore — by about 6 points. In spring 2017, as House Republicans bickered over how to repeal the health care reform law, MacArthur — then a leader of the chamber's moderate Republican caucus — brokered a deal with far-right members. It would have allowed states to circumvent some of the law's protections for people with medical conditions, if they set up high-risk insurance pools to help cover those patients.
Through that compromise, known as the MacArthur Amendment, the bill passed the House without any Democratic support. It later stalled in the Senate.
Less than a week later, appearing at that town hall in his district's Democratic stronghold, MacArthur spoke of losing his 11-year-old daughter, Grace, to a rare neurological condition, a painful story he had rarely discussed in public.
The death of MacArthur's daughter "is the very reason his constituents do not understand his actions," said Maura Collinsgru, the health care program director at New Jersey Citizen Action, a liberal watchdog group. "How could you, having had that experience, justify your votes?"
Democrats across the country have been hitting their Republican opponents hard on the issue in light of the repeal effort and a legal effort by many Republican state attorneys general to end protections for preexisting conditions. Republicans are fighting back with promises but few plans to match. During a recent forum on a local TV station, MacArthur said: "I fought to protect preexisting conditions, and I've always supported that."
The MacArthur campaign did not respond to multiple requests for an interview.
Kim, who has never held elected office, started considering whether to run when MacArthur's compromise was released, he said. But he was convinced after doctors warned him and his wife that their unborn son was dangerously underweight.
"I told my wife that if we could get through this, and if our baby is born and he is stable, I want to do what I can to hold my representative accountable for what he did," he said. Today, Kim said, his son is doing fine.
Kim has framed himself as the anti-MacArthur, vowing to hold in-person town halls once a month and reject corporate contributions.
Further complicating MacArthur's re-election prospects is his vote for the Republican tax bill, which the nonpartisan Tax Policy Center said would be most damaging for New Jersey, where it estimated 10.2 percent of households would see their federal taxes increase this year. He was the only New Jersey lawmaker to support it.
Mike DuHaime, a strategist who advised former Republican Gov. Chris Christie on his 2009 campaign, said Kim is benefiting from the "historical and partisan headwinds" facing Republican incumbents in blue states like New Jersey.
"Anyone who thinks Tom MacArthur doesn't care about those with preexisting conditions is grossly mistaken and completely unaware of the type of person he is," he wrote in an email. "He was trying to forge progress, and when you do that, you will be criticized."
But in a time of such intense political loyalties, it is unclear whether MacArthur's role in trying to repeal the Affordable Care Act would be damaging enough to oust him.
"It seems to me in this election people have chosen their tribal corners and issues have less potency overall," said Tom Moran, the editorial page editor and political columnist at the state's largest newspaper, the Star-Ledger.
"But if there is one issue that penetrates," he added, "it's health care."
The U.S. is grappling with a doctor shortage that’s expected to grow to as many as 120,000 physicians by 2030. Foreign-born doctors are vital to the national healthcare delivery system.
ATLANTA — Dr. Alluri Raju, a native of India, vividly remembers how his ethnicity prompted concern and discrimination in the southwest Georgia town of Richland. Doctors there hesitated to grant the family practitioner and general surgeon privileges to the local hospital when he arrived in 1981.
"I guess they wanted to cut me off so that I wouldn't be a competitor," he recalled.
Yet, in the 37 years Raju has been practicing in Richland, more than 20 doctors have come and gone and he's the only physician left — not just in Richland, but in all of Stewart County and neighboring Webster County, an area roughly half the size of Rhode Island with a population of more than 8,000.
"Today, I'm it," he said. And his patients, he said, treat him with respect — and not as a foreigner.
Stories like Raju's are the common thread for many immigrant doctors in the United States.
The American Medical Association said that, as of last year, 18 percent of practicing physicians and medical residents in the U.S. in patient care were born in other countries. Georgia's percentage of foreign-born doctors is similar, at 17 percent.
Yet President Donald Trump's focus on securing U.S. borders and restricting immigration — and the bitter arguments between the national political parties on the issue during midterm campaigns — have sown concerns about opportunities for foreign-born doctors.
Many of these doctors, like Raju, work in rural areas that are desperate to attract medical professionals. Yet those areas are often reliable supporters of Trump and his strict immigration policies. A recent national poll found that immigration is the top concern for Republican voters.
Some health care experts say Trump's tough stance could make it harder for rural areas such as Richland to relieve critical physician shortages.
Georgia's Republican lawmakers have considered legislation in recent years that opponents say would have restricted the rights of some immigrants. And Republican candidates for governor here campaigned in the primary this year on cracking down on illegal immigrants, though advocates for that position say bias is not the motivation, but rather the need for border security.
Raju's patients say they don't see any problem in seeking care from an immigrant. Raju has been treating Willie Hawkins, a retired road worker, for 30 years, as well as his mother and his sister.
Sometimes, Hawkins said with a smile, he has to ask the nurse what the doctor just said.
"You know, he talks a little funny," said Hawkins, 66. "But who cares?"
Maybe when Raju first came here to practice, people were a bit skeptical, Hawkins recalled. Many had never met someone from India before, he said. "But today it just doesn't matter," he said.
Foreign-born doctors are vital to the national health system. The U.S. is grappling with a doctor shortage that's expected to grow to as many as 120,000 physicians by 2030, according to the Association of American Medical Colleges.
Even now, primary care doctors are relatively scarce in certain areas of the country. Georgia has a few counties without any doctors at all, and many counties lack a pediatrician or an OB-GYN.
These immigrants help fill some of the gaps, especially in primary care, said Dr. William Salazar of Augusta University's Medical College of Georgia, who came to the U.S. from Colombia. And rural Georgia has a higher percentage of immigrant doctors than do urban areas, said Jimmy Lewis of HomeTown Health, an association of rural hospitals mostly in Georgia.
"Foreign-born doctors go to places no one wants to go," said Dr. Gulshan Harjee, a Tanzanian-born physician who co-founded the Clarkston Community Health Center, a free clinic serving mainly immigrants and refugees in metro Atlanta.
Patients' Bias
Several foreign-born doctors here recalled awkward interactions with patients, occasionally experiencing bias.
"When they think you're different, they think you're not as smart, and think they won't understand what you're saying," said Salazar. "You develop skills to overcome that.''
But patients overall are getting used to people from other countries, he added.
Saeed Raees, a pharmacist originally from Pakistan who co-founded the Clarkston clinic, said that "you'll run into a small minority who don't want to be seen by a foreign-born doctor or a Muslim doctor."
Physicians from predominantly Muslim countries face increased pressure after the Trump administration tightened its visa and immigration policies. Several doctors said that their visa applications take longer than before or are on hold, and re-entry into the U.S. after traveling was difficult.
Nearly half of Muslim physicians in the U.S. felt more scrutiny at work compared with their peers, and many said they experienced discrimination in the workplace, according to a study by Dr. Aasim Padela at the University of Chicago. Nearly a tenth of the physicians surveyed reported that patients had refused their care because they were Muslim.
There is also acceptance.
Dr. Buthena Nagi, a native of Libya, is employed as a hospitalist at Navicent Health in Macon. Nagi, 40, completed her residency at Morehouse School of Medicine in Atlanta in 2015. But to stay in the country she has to meet immigration criteria.
Most foreign physicians complete their residency in the U.S., typically on a student visa. To remain beyond that, U.S. immigration law requires them to practice in a medically underserved area for at least three years. Afterward, they can apply for a green card and, eventually, American citizenship.
Nagi wears a hijab — a traditional head covering for many Muslim women — with her scrubs, and sometimes patients and colleagues ask her about it.
"I then explain that this is part of my religion," she said. "And once the dialogue kicks in, the fear dies down, and people seem to understand that I'm not an alien from outer space."
In metro Atlanta's highly diverse DeKalb County, about 75 percent of the patients at the free Clarkston health center are immigrants, refugees or migrant workers. Up to 30 languages are spoken there. Co-founder Harjee said she speaks "only six."
Sameera Vadsariya, 37, said through an interpreter that she loves the services there. She was born in India and is here on a visa. She has no health insurance, so the free services are worth the long wait for treatment.
Most of the volunteer doctors at the Clarkston clinic are foreign-born, said Harjee. "This is a passion for them. They want to give back.''
Opportunity Lost
Belsy Garcia Manrique also wants to play a role.
At age 7, she left her home in Zacapa, Guatemala, and headed north through Mexico with her mother and sister. It was a two-week odyssey — a combination of walking and driving — up to the southern tip of Texas. Her father, Felix, who had come to the U.S. two years earlier seeking political asylum, met them and drove the family to his home in Georgia.
For many years, she dreamed of being a doctor, hoping to treat Spanish-speaking patients in the parts of northwest Georgia where she was raised.
U.S. immigration policy, however, blocked her path to medical school. She was not a legal resident. Most states, including Georgia, prevented undocumented immigrant children like Garcia Manrique from qualifying for in-state tuition at public universities.
But Garcia Manrique caught a break when President Barack Obama issued an executive order six years ago that created the Deferred Action for Childhood Arrivals program. DACA offered more than 800,000 undocumented immigrants brought to the U.S. by their parents a chance to stay without fear of deportation.
From 2012 to 2016, medical schools from California to Massachusetts accepted roughly 100 DACA students, whose families hailed from Mexico, Pakistan, Venezuela and other countries. Garcia Manrique applied to nearly 40 schools. The Stritch School of Medicine at Loyola University Chicago, the first medical school to accept DACA students, was the only one that offered her admission.
Shortly after taking office in 2017, Trump rescinded DACA, a move that has become the subject of ongoing legal and political battles. If the law stands, Garcia Manrique will be allowed to stay in the U.S. But if it's overturned, she and DACA medical trainees won't be allowed to renew their work permits.
Garcia Manrique is finishing medical school and applying for a residency program to train in family medicine. Only two Georgia medical programs — at Emory University and Morehouse College — said they would consider a DACA recipient. She applied to both.
Of her 50 applications, Garcia Manrique received interview offers from nearly a dozen programs, including ones in Illinois, California and Washington. She hasn't heard from the ones in Georgia.
And these days she isn't sure if the Georgia she knew, and the Georgia she loved, is a place where she'd feel welcome.
"After a certain time of being looked down upon, being told 'no,' going the extra mile to get the same benefits, you get tired of that," Garcia Manrique said. "I've seen many immigrants who have talent in the South move out. Why not be somewhere where you're wanted?"
The administration says it's looking to assist those left behind by the ACA. The efforts are dramatically reshaping the individual insurance market to one that looks more as it did before the 2010 law.
In the span of less than 12 hours last week, the Trump administration took two seemingly contradictory actions that could have profound effects on the insurance marketplaces set up by the Affordable Care Act.
First, officials issued guidance Monday morning that could weaken the exchanges set up for people who buy their own insurance. The new approach makes it easier for states to get around some ACA requirements, including allowing the use of federal subsidies for skimpier plans that can reject people with preexisting conditions.
Yet, the other move — a proposed rule unveiled Monday evening — could bolster ACA marketplaces by sending millions of people with job-based coverage there, armed with tax-free money from their employers to buy individual plans.
Both efforts play into the parallel narratives dominating the bitter political debate over the ACA.
The administration, frustrated that Congress did not repeal the law, say some critics and policy experts, is working to undermine it by weakening the marketplaces and the law's consumer protections. Those efforts make it easier for insurers to offer skimpier policies that bypass the law's rules, such as its ban on annual or lifetime limits or its protections for people with preexisting conditions. Congress also zeroed out the tax penalty for not having coverage, effective next year. Combined, the moves could reduce enrollment in ACA plans, potentially driving up premiums for those who remain.
The administration and Republicans in Congress say they are looking to assist those left behind by the ACA — people who don't get subsidies to help them buy coverage and are desperate for less expensive options — even if that means purchasing less robust coverage.
"These are people who were buying insurance before [the law] and then the rules changed and they could not buy it because they could not afford it," said Joe Antos, a resident scholar at the conservative American Enterprise Institute. "They have been slowly dropping out of insurance coverage altogether."
The efforts are dramatically reshaping the ACA and the individual insurance market to one that looks more as it did before the 2010 law, when regulation, coverage and consumer protections varied widely across the country.
"Some states will do everything they can to keep individual markets strong and stable. Others won't," said Sabrina Corlette, research professor at the Center on Health Insurance Reforms at Georgetown University.
So what expectations should consumers have? Here are three key takeaways:
Protections for preexisting health problems are uncertain.
Polls show that keeping the ACA's guarantees on coverage for people with medical problems is a top concern for Americans, and Democrats have made their defense of the health law a key part of their midterm election campaigns.
Republicans have gotten that message and even those who voted to repeal the ACA or joined a lawsuit by 20 red states to overturn it now say they want to protect people with preexisting conditions. Still, GOP lawmakers have not introduced any plan that would be as protective as the current law.
In August, the administration released a rule allowing expanded use of short-term plans, which are less expensive than ACA policies. To get those lower prices, most of these plans do not cover prescription drugs, maternity care, mental health or substance abuse treatments.
The move is unlikely to benefit people with health problems, as short-term plans can reject people with preexisting conditions or decline to cover care for those medical problems.
Under the rule, insurers can sell them starting in 2019 for up to a year's duration, with an option to renew for up to three years, reversing an Obama-era directive that limited them to 90 days.
Administration officials estimate such plans could draw 600,000 new enrollees next year, and others have estimated the numbers could be far higher. The concern is if many healthy people in 2019 switch out of the ACA market and choose short-term plans, premiums will rise for those who remain, including those with preexisting conditions or make the ACA market less attractive for insurers.
Where you live matters more.
One of the biggest changes ushered in with the ACA was a standard set of rules across all states.
Before the law took effect, consumers buying their own coverage saw tremendous variation in what was offered and what protections they had, depending on the state where they lived.
Most states, for example, allowed insurers to reject people with medical conditions. A few states required insurers to charge similar premiums across the board, but most allowed wide variations based on age, gender or health. Some skimpy plans didn't cover prescription drugs, chemotherapy or other medical services.
By standardizing the rules and benefits, the ACA barred insurers from rejecting applicants with medical conditions or charging them more. Women and men get the same premium rates and insurers could charge older people no more than three times what they charged younger ones.
Under the new guidance issued this week giving states more flexibility on what is offered, consumers could again see a wide variation on coverage, premium rules and even subsidy eligibility.
"It shifts pressure to state politicians," said Caroline Pearson, a senior fellow at NORC, a nonpartisan research institution at the University of Chicago. That could play into the calculus of whether a state will seek to make broad changes to help people who cannot afford ACA plans, even if the trade-off affects people with medical conditions.
"You risk making some worse off by threatening those markets," said Pearson. "That is always going to be hard."
Millions more will join the "buy-your-own" ranks.
The proposed rule released Tuesday allows employers to fund tax-free accounts — called health reimbursement arrangements (HRAs) — that workers can use to buy their own coverage on the ACA marketplaces.
The administration estimates about 10 million people would do so by 2028 — a substantial boost for those exchanges, which policymakers say never hit the enrollment numbers needed to attract enough insurers and hold prices down.
John Barkett, senior director of policy affairs at Willis Towers Watson, a benefits consulting firm, said he expects employers to "seriously consider" the new market. The infusion of workers will improve options by attracting more insurers, he added.
"These people coming in will be employer-sponsored, they'll have steady jobs," Barkett noted, and will likely stick with coverage longer than those typically in the individual market.
Currently more than 14 million people buy their own insurance, with about 10 million of those using federal or state ACA marketplaces. The others buy private plans through brokers.
The proposed rule won't be finalized for months, but it could result in new options by 2020.
If these workers seeking coverage are generally healthy, the infusion could slow premium increases in the overall ACA marketplace because it would improve the risk pool for insurers.
But, if employers with mainly higher-cost or older workers opt to move to the marketplaces, it could help drive up premiums.
In an odd twist, the administration notes in the proposed rule that the ACA has provisions that could protect the marketplace from that type of adverse selection, which can drive up prices. But most of the protective factors cited by the rule have been weakened, removed or expired, such as the tax penalty for being uninsured and the federal subsidies for insurers to cover lower deductibles for certain low-income consumers.
Benefits consultants and policy experts are skeptical about how many companies will move to the HRA plan, given the tight labor market. Continued uncertainty about the fate of the ACA marketplace may keep them reluctant to send workers out on their own, they say.
Health benefits are a big factor in attracting and retaining workers, said Chris Condeluci, a Washington attorney who previously worked for Sen. Chuck Grassley (R-Iowa) and served as counsel to the Senate Finance Committee during the drafting of the ACA.
"Most employers believe their group health plan will provide better health coverage than an individual market plan," he said.
Proposition 8 would wipe out DaVita's earnings in California, according to recent investment firm reports. Passing the initiative 'would be so devastating,' to the tune of $450 million a year, that DaVita 'would likely walk away from the state altogether.'
It's been a year of playing defense for DaVita Inc., one of the country's largest dialysis providers.
A federal jury in Colorado this summer awarded $383.5 million to the families of three of its dialysis patients in wrongful death lawsuits. Then this month, the Denver-based company announced it would pay $270 million to settle a whistleblower's allegation that one of its subsidiaries cheated the government on Medicare payments.
But its biggest financial threat is a ballot initiative in California that one Wall Street firm says could cost DaVita $450 million a year in business if the measure succeeds.
Despite these recent hits, the company continues to rake in profits and receive favorable ratings from stock analysts. Its shares are trading at about $65 a share, only about 19 percent below a 52-week high set in January. That's largely because DaVita controls about one-third of a growing market, health experts say.
"They don't really have many rivals, and they perform a necessary, lifesaving service," said Leemore Dafny, a professor of business administration at Harvard Business School. "If you're producing something people want to buy and you're the only one making it, people are going to buy it."
Patients with chronic kidney failure often need dialysis to filter the impurities from their blood when their kidneys can no longer do that job.
And as Americans live longer and get heavier, more people become diagnosed with kidney disease and possibly need dialysis. In 2015, 124,114 new patients received dialysis, up from 94,702 in 2000, a 31 percent increase, according to the U.S. Renal Data System.
DaVita is one of the largest dialysis providers in the country, operating more than 2,500 clinics nationwide. In California, the company operates 292 clinics, half of all chronic dialysis clinics in the state.
Its parent company, DaVita Inc., reported $10.9 billion in revenue last year and $1.8 billion in profits, almost all of which came from its dialysis business.
This year, company officials project the dialysis group will bring in $1.5 billion to $1.6 billion in profits. It's a big turnaround for a corporation that could barely make payroll in 1999, when it was under review by the Securities and Exchange Commission for questionable accounting practices. Its success has largely been credited to CEO Kent Thiry, a colorful personality who has dressed up as a Musketeer and ridden a horse into corporate meetings to rally workers.
Now those big profits — generated from treating sick patients — has put a target on the company's back, as well as that of its biggest competitor, Fresenius Kidney Care.
The Service Employees International Union succeeded this year in placing Proposition 8 on California's Nov. 6 ballot, which would limit dialysis center commercial revenues to 115 percent of patient care costs. The ballot fight pits a well-funded industry against labor and the California Democratic Party.
DaVita declined to make anyone available for this article, but in a statement said Proposition 8 "will limit patients' access to life-saving dialysis treatments, jeopardizing their care."
Last year, roughly two-thirds of DaVita's dialysis revenue came from government-based programs, such as Medicare and Medicaid. But that isn't enough to cover its costs, according to the company's 2017 annual report, which states that DaVita loses money on each Medicare treatment it provides. (Medicare covers dialysis for people 65 and older, and for younger patients after private insurance has provided coverage for 30 months.)
Instead, DaVita generates profits from commercial health plans, which it acknowledges pay "significantly higher" rates than government programs. The ballot measure targets those higher rates, which Dafny describes as "their bread and butter."
The prospect of the measure passing led DaVita to delay or cancel plans to open new clinics in California despite growing patient demand, Javier Rodriguez, chief executive officer of DaVita Kidney Care, told investors on a call in May, according to the online equity research website Seeking Alpha.
A few months later, Rodriguez declined to provide a dollar amount when asked how the initiative would impact the company. Rather, he warned investors that it would become "unsustainable" for the industry to treat the estimated 66,000 dialysis patients in California, should the measure succeed.
Wall Street analysts agree that Proposition 8 would wipe out DaVita's earnings in California, according to recent reports issued by investment firms J.P. Morgan and Baird. Passing the initiative "would be so devastating," to the tune of $450 million a year, that DaVita "would likely walk away from the state altogether," according to a March Baird report.
DaVita has poured $66.6 million into the opposition campaign as of Oct. 25, and rival Fresenius has contributed $33.6 million. That dwarfs $17.3 million in union contributions in support of the measure, according to campaign records filed with California's secretary of state office.
Both Wall Street firms conclude that Proposition 8 is likely to fail, citing the industry's massive spending and the union's record of failure at the polls on other issues.
The company's legal troubles don't worry stock analysts, either; Baird's October report on DaVita's financial performance dedicates just two sentences to them. It notes that DaVita "is subject to numerous ongoing government investigations and inquiries, similar to most large-scale, high-profile Medicare providers."
There are no specific references to the Colorado jury award this summer, which the company is appealing, over the death of three patients who died of cardiac arrest after treatment at DaVita clinics. Nor was there concern about this month's $270 million settlement over Medicare billing.
That's because those incidents are seen by investors as the cost of doing business — one-time hits that don't affect a company's earnings power in the future, said Matthew Gillmor, a senior research analyst at Baird.
"Almost all companies I follow, at some point, have had to pay a fine to the government," Gillmor said.
Thiry, DaVita's CEO, acknowledged that settlements, which aren't good public relations, are a reality for large corporations, when The Denver Post asked him last year about the company's previous legal battles.
"If, in a trial, you are found to be wrong on even a small part of the case, it could mean that you are excluded from Medicare, which typically would mean bankruptcy for your company," Thiry said. "So, you are essentially forced to settle."
Stanford Health Care operates the largest hospital system in both cities where the price cap proposal is on the ballot. Stanford officials say the measures could undermine quality.
At a time of mounting national anger about rising health care prices, the country's largest union of health workers has sponsored ballot measures in two San Francisco Bay Area cities that would limit how much hospitals and doctors can charge for patient care.
The twin measures in Palo Alto and Livermore, sponsored by the Service Employees International Union-United Healthcare Workers West, take aim primarily at Stanford Health Care, which operates Stanford Hospital and Clinics, the facility with the third-highest profits in the country from patient care services, according to a 2016 study.
The union also is sponsoring Proposition 8, a statewide measure that would impose a cap on profits for dialysis clinics. Together, the state and local measures seek to draw on public outrage over sky-high medical prices. And, for municipalities, they amount to a novel and untested effort to rein in those prices through the ballot box.
"I've been in this field almost 50 years, and I've never seen a local government regulating hospital prices," said Paul Ginsburg, director of public policy at the Schaeffer Center for Health Policy & Economics at the University of Southern California. A number of states set hospital rates in the 1970s, and two states, Maryland and West Virginia, do so today, he said.
Opponents question the legal authority of cities to regulate health care pricing, and they predict a flood of litigation against the measures if they pass. The city councils of both cities oppose the proposals, arguing that local officials with no expertise in health care costs would be required to create a new bureaucracy to regulate them.
Stanford Health Care officials say the measures could undermine quality. "It would threaten [the system's] ability to provide top-quality health care to patients from Palo Alto and across the region," according to a September statement from the system.
Ginsburg expressed skepticism. "Of course, you could cut rates too much and harm hospitals financially," he said. “But if done with intelligence, you could accomplish some price reduction without harming quality."
For the union, the ballot measures could help it gain leverage in future bargaining or organizing efforts with Stanford and other hospitals. Stanford Health Care operates the largest hospital system in both cities where the price cap proposal is on the ballot. Stanford has opened, has acquired or is building health care centers with clinics and specialty services in Emeryville, Pleasanton and Redwood City — Bay Area cities where the SEIU-UHW tried but failed to place similar price-control measures on local ballots.
But union officials say their motive is simply to rein in prices. "Stanford Health is nonprofit. They don't pay property taxes or incomes taxes," said Sean Wherley, an SEIU-UHW spokesman. "Taxpayers are subsidizing their operations and getting wrung out by over-the-top prices."
Stanford and other health systems have been on a buying spree in recent years acquiring hospitals and physician practices, and this concentration of ownership has stifled market competition and further boosted prices for insurers and patients.
The Palo Alto and Livermore initiatives, which also affect other medical systems in the cities, would cap prices charged by hospitals and other health care providers at 115 percent of "the reasonable cost of direct patient care."
And there, some experts say, lies the rub.
"What is a seemingly simple idea — limiting prices to 115 percent of 'costs' — is neither simple in execution, nor concept," said Benedic Ippolito, a research fellow at the American Enterprise Institute who studies health care financing. "What costs are acceptable? How will we stop providers from increasing costs as much as possible" to compensate for the cap?
Under the initiatives, hospitals and other medical providers would be obliged to pay back any charges above the cap each year to private commercial — but not government — insurers, and to patients who pay for their own care. They would also owe the cities a fine equal to 5 percent of the excess charges. Fines collected by the cities could be used to pay for enforcing the laws.
Stanford estimates that Proposition F, the Palo Alto measure, would reduce the health system's budget by 25 percent, forcing it to make cutbacks and possibly end essential services, said David Entwistle, the health system's president and chief executive officer.
Livermore would need to spend $1.9 million a year on the staff required to implement Measure U — its version of the proposal — and would likely incur another $750,000 to $1 million in legal and startup costs, according to an analysis conducted for the city by Henry Zaretsky, a health economist who has worked for the state and the California Hospital Association.
Patients in the wealthy region expect high-quality services but also can be savvy consumers and passionate voters. It is an open question whether the measures would pass.
Industry consolidation is far more pronounced in Northern California than in Southern California, according to a recent study from the University of California-Berkeley. As a result, inpatient hospital prices in the north were 70 percent higher and outpatient costs as much as 55 percent higher than in the south. The price disparities, even within the Northern California region, can be dramatic.
For instance, independent doctors in the Bay Area are reimbursed, on average, a median $2,408.45 for a routine vaginal delivery, which includes prenatal and postnatal visits, according to a 2017 Kaiser Health News analysis of claims data from Amino, a health cost transparency company. That compares with $5,238.13 for the same bundle of services for Stanford physicians (and $8,049.84 for doctors employed by the University of California-San Francisco).
The higher cost of medical care also pushes up insurance premiums for patients. Health plans purchased on the state insurance exchange were 35 percent higher in Northern California than in Southern California, the 2018 UC Berkeley study showed.
Earlier this year, California Attorney General Xavier Becerra took aim at medical industry consolidation and the high prices associated with it. He sued Sutter Health, one of the nation's largest health systems, saying it was systematically overcharging patients and illegally driving out competition in Northern California.
To C. Duane Dauner, a former president and CEO of the California Hospital Association, the ballot proposals are "a power play by SEIU-UHW to put pressure on Stanford Health Care." The union wants Stanford "to be neutral when they try to organize employees in Redwood City, Emeryville, Pleasanton and Livermore," said Dauner, who heads the campaign committee opposing both measures.
Larry Tramutola, a veteran campaign consultant who is not involved on either side, agrees.
"I don't think it has anything to do with controlling health care prices," said Tramutola, who recently managed successful local initiatives to tax sodas and ban menthol cigarettes. "It's about bargaining. Win or lose on this, other hospitals in other places will take notice and realize that SEIU is a formidable foe."
Protect Our Local Hospitals and Health Care, the campaign committee opposing the measures, has raised $4.2 million so far this year. The union's political action committee has spent $1.5 million in support of the initiatives.
If the push is successful, about 62,000 Idaho adults would be added to the program that covers 73 million low-income Americans. It would be a major advance for the ACA into one of the most conservative parts of the country.
BOISE, Idaho — Standing outside the gun shop she co-owns, next to her SUV sporting "NRA" on the license plate, Christy Perry pledges full support for President Donald Trump.
"He's doing a good job," said Perry, a four-term Republican member of the Idaho legislature who has voted for a litany of conservative causes, including weakening labor unions, restricting abortion and boosting charter schools.
With those credentials, Perry hopes for another big win on Election Day — one that puts her at odds with Trump and GOP orthodoxy.
She's helping lead the drive to persuade state voters to expand Medicaid — a central tenet of the Affordable Care Act, the 2010 law embraced by Democrats and derided by many Republicans.
Perry has been pushing for Medicaid expansion the past several years in the state legislature, but those efforts were thwarted by top House leaders. Now a ballot initiative, Proposition 2, puts the matter before Idaho voters.
Perry said Medicaid coverage is desperately needed by people struggling in low-wage jobs and the economics make sense for the state given the federal government will pay a 90 percent share. An expansion will reduce or eliminate the need for other Idaho-funded programs to help the uninsured, she said.
She said the state can't wait any longer.
"The longer you wait, the more people die" because they miss out on care, she said.
If the push is successful on Nov. 6, about 62,000 Idaho adults would be added to the state-federal health insurance program that covers 73 million low-income Americans. It would be a major advance for Obamacare into one of the most conservative parts of the country.
Idaho is one of the remaining 17 GOP-controlled states where lawmakers have steadfastly resisted expanding Medicaid.
But voters in Idaho, Nebraska and Utah will decide next month whether to buck their political leaders and go forward with the expansion. The issue is also on the ballot in Montana, which expanded Medicaid in 2016. There, residents will decide whether to continue it past 2019.
Of those states, Idaho is arguably the least politically hospitable for Medicaid expansion. Trump carried Idaho by the largest margin — nearly 32 percentage points.
Last year, Maine became the first state to approve expanding Medicaid via a ballot referendum, although the GOP governor has stalled implementation.
Unlike Maine, where political power has been split between Democrats and Republicans in recent years, Idaho, Utah and Nebraska are solidly GOP territory.
Trump and Republican congressional leaders have vowed to repeal the health law, which made expansion possible by providing the bulk of the funding for those who qualify for new coverage.
Perry, 50, doesn't see a problem getting Trump voters to back the expansion. She said that the Republican failure to repeal the law last year opened the door for conservative states to go forward.
"I think people here listen to that and it now falls to states to go ahead" with expansion, she said.
Supporters of the referendum were successful at garnering 70,000 signatures to put the vote on the ballot, but they face a steep challenge educating the electorate about the complexities of Medicaid financing.
Tim Dunnagan, dean of the College of Health Sciences at Boise State University, said few Idaho voters know that most states — including neighboring Oregon and Washington — have already expanded Medicaid. Because the issue can be confusing, he said, voters may gravitate to their long-held concerns about paying more taxes and government overreach.
"There is a strong sentiment that if the federal government is involved, it is not a good thing," he said. "There's a fierce individualism out in the West."
Perry and the broad coalition endorsing the referendum — including teachers, employers, county sheriffs and the health industry — seek to remind voters that they are already paying for the health law's provisions through their federal taxes and the expansion would bring $400 million in federal funds into the state.
The expansion would cover residents with incomes below 138 percent of the federal poverty level, or nearly $17,000 a year for an individual. Currently, Idaho adults who do not have children and are not disabled are not eligible for Medicaid. Those with children can only qualify with incomes up to 26 percent of the poverty level, or $3,156 a year.
The expansion also would eliminate a gap for residents whose income is too low to qualify for government subsidies to buy private coverage but who earn too much to qualify for Medicaid.
Supporters have canvassed neighborhoods across the state in recent weeks. Hundreds of volunteers use lists of registered voters and a special app on their phone to detail their results.
On a recent evening, about 20 people gathered about 10 miles east of downtown Boise, where a field organizer gave them voter lists and instructions on how to approach homeowners.
Tracy Olson, 54, a nurse turned real estate agent, and Jill Galanter, 55, a physical therapist, went to an upper-income planned community. About two-thirds of the people they met said they support expansion, and most of the rest had not heard about it. Only a couple of people said they oppose the ballot question.
In their one-minute pitch, Olson and Galanter explained the coverage gap for low-income residents and the millions in federal dollars the state can gain by expanding. They didn't mention the ACA. That's not an oversight, organizers said.
"Obamacare has a negative connotation here," Perry said.
Mike Brown, 50, an engineer, told Olson he didn't know the issue but added that his health costs have soared in recent years. He nodded as Olson explained whom the expansion would help.
"I can sympathize," he said. They recorded him as a "leaning yes."
Richard Rapp, 75, a retired head of the career center at Boise State University, said he will support the expansion for humanitarian reasons. "Too many people don't have adequate coverage, and that ends up costing us all," he said.
Later that week, another volunteer, Lauren Necochea, also found support in the Nampa area, west of Boise.
Norm Holm, 67, listened to her pitch. "It makes sense to me," said Holm, a registered Republican. "Everyone deserves a decent shot at health care."
Asked if he knew that the Medicaid expansion is part of the ACA, Holm shook his head. "If they can't do away with it, maybe this is a way to make it better," he said, adding that he believes the health law has good and bad parts.
In contrast, opponents of the referendum stress how Medicaid expansion is part of what they call the "failed Obamacare."
The Idaho Republican Party and the conservative Idaho Freedom Foundation are fighting the ballot initiative. Foundation officials say it would divert dollars that could be spent on roads and education.
"Medicaid expansion is a cornerstone of Obamacare, which has failed to cover everyone and has led to increasing health costs," said Fred Birnbaum, vice president of the foundation.
His group plans to run radio commercials, use social media and put out flyers.
Lawmakers opposed to expanding Medicaid have argued that the state could not afford its share of the cost without having to raise taxes. Under the law, the federal government pays about 90 percent of the costs for expansion and states cover the rest.
But a state-funded report this year found it would cost Idaho relatively little — $105 million over 10 years, which includes savings from state and county funds that would no longer be needed to help the uninsured. Idaho's budget tops $3 billion a year.
Brad Little, the GOP nominee for governor who is widely expected to win in November, said he would abide by the will of the voters.
Perry is not the only Republican state lawmaker who has come out in support of expansion, but she is one of the most prominent. Perry tried — and failed — to get lawmakers to expand Medicaid. She is not running for re-election.
"Christy is well-known among GOP women and well-liked," said Toni Lawson, vice president of government relations at the Idaho Hospital Association, which supports the initiative. She said persuading GOP women to vote for expansion will be key to a victory.
Perry said her gun store ownership and mainstream conservative values will help gain voters' trust on Medicaid.
"Idaho is a conservative, Christian and right-to-life state, and Medicaid expansion fits right in with our morals and values we have," she said. "It's about doing the right thing."
Medicaid enrollment fell by 0.6 percent in 2018 — its first drop since 2007 — due to the strong economy and increased efforts in some states to verify eligibility, a new report finds.
But costs continue to go up. Total Medicaid spending rose 4.2 percent in 2018, same as a year ago, as a result of rising costs for drugs, long-term care and mental health services, according to the study released Thursday by the Kaiser Family Foundation. (Kaiser Health News is an editorially independent program of the foundation.)
States expect total Medicaid spending growth to accelerate modestly to 5.3 percent in 2019 as enrollment increases by about 1 percent, according to the annual survey of state Medicaid directors.
About 73 million people were enrolled in Medicaid in August, according to a federal report released Wednesday.
Medicaid, the state-federal health insurance program for low-income Americans, has seen its rolls soar in the past decade — initially as a result of massive job losses during the Great Recession and in recent years when dozens of states expanded eligibility using federal financing provided by the Affordable Care Act. Thirty-three states expanded their programs to cover people with incomes under 138 percent of the federal poverty level, or an income of about $16,750 for an individual in 2018.
Medicaid spending and enrollment typically rise during economic downturns as more people lose jobs and health benefits. When the economy is humming, Medicaid enrollment flattens as more people get back to work and can get coverage at work or can afford to buy it on their own. The national unemployment rate was 3.7 percent in September, the lowest since 1969.
The falling unemployment rate is the main reason for the drop in Medicaid enrollment, but some states have reduced their rolls by requiring adults and families to verify their eligibility. Arkansas, for example, has cut thousands of people after instituting new steps to confirm eligibility.
The brightening economic outlook for states has led many to increase benefits to enrollees and payment rates for health providers.
"A total of 19 states expanded or enhanced covered benefits in fiscal 2018 and 24 states plan to add or enhance benefits for the current fiscal year, which for most states started in July," the Kaiser report said. "The most common benefit enhancements reported were for mental health and substance abuse services. A handful of states reported expansions related to dental services, telehealth, physical or occupational therapies and home visiting services for pregnant women."
A dozen states increased pay to dentists and 18 states added to primary care doctors' reimbursements for fiscal year 2019.
Medicaid covers about 20 percent of U.S. residents and accounts for nearly one-sixth of health care expenditures. Nearly half of enrollees are children.
Overall, the federal government pays about 62 percent of Medicaid costs with state's picking up the rest. Poorer states get a higher federal match rate.
Seventeen Republican-controlled states have not expanded Medicaid. For individuals accepted into the program as part of the ACA expansion, the federal government paid the full cost of coverage from 2014 through 2016. It will pay no less than 90 percent thereafter.
In 2018, the states' share of spending rose 4.9 percent. This was the first full year that states were responsible for part of the cost of the expansion. States expect their spending will grow about 3.5 percent in 2019.
Robin Rudowitz, one of the authors of the study and associate director of the Kaiser Commission on Medicaid and the Uninsured, said the survey found many states were using Medicaid to address the opioid crisis by expanding benefits for substance disorders and also by implementing tougher restrictions on prescriptions.
"Almost every governor wants to do something, and Medicaid is generally a large part of it," she said.
While the Trump administration's approval of work requirements for some adults on Medicaid has generated controversy over the past year, the report shows that states are making many other changes to the program, such as increasing benefits and changing how it pays providers to get better value.
Last year, nearly 60 percent of Maine residents voted to expand the state's Medicaid program — an option provided by the Affordable Care Act that would extend health insurance to tens of thousands of the state's low-income people.
But the state's Republican governor, Paul LePage, a longtime opponent of Medicaid expansion, has refused to implement the policy because he doesn't want to raise taxes to pay the state's share of the cost.
The impasse highlights how the intense political push and pull over Medicaid expansion persists even when voters bypass legislators and decide the issue directly at the ballot box. Nevertheless, four more states — Idaho, Montana, Nebraska and Utah — will give voters in November's elections the opportunity to resolve the dispute.
"It's always treacherous" for politicians to raise taxes, said Matt Salo, who heads the National Association of Medicaid Directors. "But there are ways around it. You can figure out ways that are politically palatable."
When the ACA's Medicaid expansion took effect in 2014, proponents say, it set up an enticing deal. It allowed states to cover people with incomes up to 138 percent of the federal poverty level, including childless single adults.
The federal government paid the entire cost of the new enrollees. In 2017, states were to take on 5 percent of those costs. By 2020, that amount will increase to 10 percent.
States that didn't pursue the expansion pay as much as half the cost of coverage. And, in 2018, median eligibility for a family of four was 43 percent of the poverty level, or about $10,800. No childless adults were eligible.
So far, 33 states plus the District of Columbia have opted to expand, extending coverage to almost 12 million Americans, according to federal estimates last year. In those states, the expense ranges from tens of millions of dollars to hundreds of millions.
Rather than being a cash drain, many health policy researchers and economists note, expansion has generally boosted state economies, with higher employment, reduced state spending on health care services for the uninsured and consumer spending elsewhere that would have gone to health care.
"The state savings are so significant, they make it much more manageable," said Adam Searing, an associate professor of practice at Georgetown University's Center for Children and Families. "The issue of how it gets paid for — it's still an important issue, but it's not as front and center."
Different approaches work for different states, Salo said, and all invite political complications.
In Montana, voters are considering Initiative 185, a ballot question that would continue the state's Medicaid expansion and fund it by increasing what is known as a "sin tax" on tobacco products, including electronic cigarettes.
It's a counterintuitive double whammy in such a conservative state: persuading voters first to favor an Obamacare policy, and second to finance it with a tax hike.
By taking on cigarettes, the campaign has incurred the wrath of Big Tobacco, which has put forth more than $12 million in contributions and expenditures to fight the measure.
"Anytime you go up against the tobacco industry, you are mainly going to have them as your opponent," said Amanda Cahill, who directs government relations for Montana's American Heart Association chapter and is part of the "Yes on I-185" campaign.
Voters can be skittish about a tax increase, she said, but many are receptive to the campaign's argument that it pays off in the long term.
New Hampshire took a parallel "sin tax"-type approach. It uses money from an alcohol tax to help fund expansion, a deal negotiated this year.
In Utah, voters will consider newly expanding Medicaid and funding it with a 0.15 percent increase to the state's sales tax, though the hike would exempt groceries. Current polling suggests strong voter support. Nebraska and Idaho also have Medicaid expansion on the ballot, though they would punt the funding question to state legislatures.
Other states have tried a different strategy: shielding consumers from direct taxes and instead financing expansion through taxes on industry players that benefit from Medicaid expansion. The most notable example: hospitals. For these facilities, reducing the number of uninsured, low-income people reduces the burden of uncompensated care and improves their bottom line. Research from states that have already expanded Medicaid supports this idea.
Virginia, Oregon and Colorado already have such taxes or fees in place. (Oregon voters in January approved a tax on both health insurance and hospitals to fund expansion.)
But it hasn't been easy. Virginia's legislature voted this summer to expand Medicaid eligibility after failing five times. During Statehouse debates, funding was a "very significant concern," said Michael Cassidy, president of the Commonwealth Institute for Fiscal Analysis, a Richmond-based think tank that has long supported the policy.
Proponents of expansion showed economic projections that Virginia would benefit financially, since fewer uninsured people would need state-funded health services, and the injection of federal cash would boost the state economy.
The legislature eventually approved a tax on hospitals, by garnering support from their trade group, the Virginia Hospital and Healthcare Association. But the path to approval was "quite contentious," Cassidy said. Critics argued the cost was too great and could drive up health care expenses.
Medicaid advocates haven't begun planning ballot initiatives for 2020 yet, but there are six states that haven't expanded eligibility where voters could take on the question directly: Florida, Mississippi, Missouri, Oklahoma, South Dakota and Wyoming.
As political analysts have long argued, the issue isn't entirely about funding. States can surmount that obstacle if there is political will.
"If you're talking about why did certain states not do the expansion, the fear of the cost — while a real issue — has never been within the top three of the actual reasons why they actually didn't do it," Salo said. "It all has been political and ideological."